13G Filing: JPMorgan Chase & Co and Kite Pharma Inc. (KITE)

Page 1 of 3

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
JPMORGAN CHASE CO 13-6 1,184,466 0 1,214,765 0 1,215,790 2.1%

Page 1 of 3 – SEC Filing



UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934

(Amendment No.
01)*
KITE PHARMA, INC. 

(Name
of Issuer)
Common Stock, par value $0.001 per share

(Title of Class of Securities)

49803L109

(CUSIP Number)

September 29, 2017

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x
Rule
13d-1(b)

o
Rule
13d-1(c)

o
Rule
13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to
be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


Follow Kite Pharma Inc. (NASDAQ:KITE)

Page 1 of 3